Mariya Rozenblit, MD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Biography
Dr. Mariya Rozenblit is an Assistant Professor of Medicine in the section of Medical Oncology and cares for patients with a clinical focus on breast cancer. She completed her Fellowship in Medical Oncology-Hematology at Yale, Residency in Internal Medicine at NYU, and received her medical degree from Icahn School of Medicine. She is involved in educating medical students, residents, and fellows at Yale. Outside of the clinic, her focus is translational research with an interest in biomarker driven trial development in breast cancer.
In 2020, she was the recipient of the ASCO Conquer Cancer Foundation Young Investigator Award for her project, “Using single nucleotide variants of high functional importance to predict the risk of developing breast cancer in young women with high risk family history.” This award is for promising investigators to encourage and promote quality research in clinical oncology. In 2022, she was the recipient of the Susan G. Komen Career Catalyst Research Grant for her project, "Curing de novo oligometastatic HER2+ breast cancer". This grant is to foster promising breast cancer researchers by providing support for up to three years.
Last Updated on May 22, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Center for Breast Cancer
- Genomics, Genetics, and Epigenetics
- Internal Medicine
- Medical Oncology
- Medical Oncology and Hematology
- Palade House Affiliates
- Yale Cancer Center
- Yale Medicine
Education & Training
- Internal Medicine Resident
- NYU Langone Medical Center (2018)
- MD
- Icahn School of Medicine at Mount Sinai (2015)
- BA
- Columbia University, Biology (2009)
Research
Publications
2025
Erratum: De Novo Oligometastatic Breast Cancer
Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. Erratum: De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2025, 43: 2758-2758. PMID: 40690726, DOI: 10.1200/jco-25-01626.Peer-Reviewed Original ResearchQuantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
Du J, Quintanilha J, Huang R, Heilmann A, Kahn A, Rozenblit M, Chiang A, Pusztai L, Krop I, Winer E, Graf R, Mills J, Gasco Hernandez A, Levy M, Lustberg M. Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer. Journal Of Clinical Oncology 2025, 43: 1065-1065. DOI: 10.1200/jco.2025.43.16_suppl.1065.Peer-Reviewed Original ResearchMetastatic breast cancerComprehensive genomic profilingPositive percent agreementClinicogenomic databaseTumor fractionCtDNA sheddingBC patientsReflex testBreast cancerFirst-line standard of careResistance to estrogen deprivationTissue comprehensive genomic profilingMetastatic breast cancer patientsFalse negative rateFoundationOne Liquid CDxFirst-line standardMutation-negative casesCohort of patientsStandard of careESR1 mutationsTumor genotypeEstrogen deprivationFirst-lineAromatase inhibitorsClinical impactGenomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Rozenblit M, Huang R, Pusztai L. Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. The Oncologist 2025, 30: oyaf089. PMID: 40421962, PMCID: PMC12107548, DOI: 10.1093/oncolo/oyaf089.Peer-Reviewed Original ResearchConceptsHomologous recombination deficiencyDe novo stage IV breast cancerStage IV breast cancerPrimary breast cancerIV breast cancerStage I-III cancerStage I-IIIBreast cancerGenomic alterationsFrequency of genomic alterationsHER2+ cancersI-IIITargetable genomic alterationsGenomic landscapePlatinum-based treatmentWild-type cancersHR repairCancer-related genesER+/HER2- cancersLate relapsePrimary tumorFoundation MedicinePIK3CA mutationsMutation statusNo significant differenceAccelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Abraham S, Parekh J, Lee S, Afrin H, Rozenblit M, Blenman K, Perry R, Ferrucci L, Liu J, Irwin M, Lustberg M. Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers. Cancer Medicine 2025, 14: e70929. PMID: 40322791, PMCID: PMC12051034, DOI: 10.1002/cam4.70929.Peer-Reviewed Original ResearchConceptsBiological age of patientsLeukocyte telomere lengthInterleukin-6Treatment-related toxicityAge of patientsTherapy-induced toxicityExpression of p16INK4aPredictors of toxicityStatus of biomarkersMarkers of cellular senescenceRadiation therapyBiological ageCancer patientsCancer therapyFunctional reserveAging biomarkersPhysiological reserveCancer treatmentCancerConfirmatory studiesTherapyClinical practiceFunctional capacityPatientsFunctional statusGenomic alterations in normal breast tissues preceding breast cancer diagnosis
Dai J, Rozenblit M, Li X, Shan N, Wang Y, Mane S, Marczyk M, Pusztai L. Genomic alterations in normal breast tissues preceding breast cancer diagnosis. Breast Cancer Research 2025, 27: 60. PMID: 40264151, PMCID: PMC12013151, DOI: 10.1186/s13058-025-02018-5.Peer-Reviewed Original ResearchConceptsHistologically normal breast tissueSomatic mutationsNormal breast tissueGenomic alterationsBreast tissuePre-DiagnosisMethodsWhole exome sequencingCancer diagnosisCancer predisposition genesCOSMIC signature 3Breast cancerCancer hallmark genesBreast tissue of womenBreast cancer diagnosisEvading growth suppressorsVariant burdenMutational signature analysisRegulatory genesAffected genesExome sequencingGermline variantsTissue of womenTissues adjacent to cancerDNA repairGenomic instability
2024
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 209: 21-26. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.Peer-Reviewed Original ResearchHigh-risk family historyFamily historyRare germline variantsCancer riskSNP-set kernel association testAssociated with breast cancer riskCancer casesContribution of family historyEarly-onset breast cancerCancer prevention clinicBreast cancerBreast cancer riskKernel association testBreast cancer casesCancer-predisposing genesGermline variantsGermline pathogenic variantsYoung womenPrevention clinicSKAT-OBurden testsPathogenic variantsExome sequencing dataAssociation TestLevel alterationsCurrent management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN guidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiation
2023
Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.Peer-Reviewed Original ResearchComprehensive genomic profilingBreast cancerYoung womenGenomic alterationsAdvanced breast cancerPD-L1 expressionTargetable genomic alterationsWorse clinical outcomesTime of diagnosisTumor mutational burdenCross-sectional studyBreast cancer casesFoundation MedicineClinical outcomesPIK3CA mutationsCancer casesEstrogen receptorMutational burdenOlder womenConclusionOur findingsTotal casesBreast tumorsTumor tissueBRCA1 mutationsMicrosatellite instabilityMolecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.Peer-Reviewed Original ResearchConceptsHER2 mRNA levelsIHC 0MRNA levelsOncotype DX recurrence score resultsEstrogen receptor-positive breast cancerReceptor-positive breast cancerCurrent adjuvant chemotherapyOncotype DX assayRecurrence Score resultsPositive breast cancerInvasive breast carcinomaIHC score 0Adjuvant chemotherapyQuantitative RT-PCRBreast carcinomaPositive statusScore 0Breast cancerStage IYale cohortHigher mRNA levelsCancerRT-PCRPatientsHER2De Novo Oligometastatic Breast Cancer
Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.Peer-Reviewed Original Research
Clinical Trials
Current Trials
A pilot study to evaluate biomarkers and safety of dapagliflozin concomitant with neoadjuvant therapy for patient with HER2-negative early-stage breast cancer and hyperinsulinemia
HIC ID2000033529RoleSub InvestigatorPrimary Completion Date12/31/2025Recruiting ParticipantsPhase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
HIC ID2000033661RoleSub InvestigatorPrimary Completion Date06/30/2025Recruiting ParticipantsEMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
HIC ID2000033997RoleSub InvestigatorPrimary Completion Date10/15/2027Recruiting ParticipantsA Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
HIC ID2000033838RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting ParticipantsGenderBothAge50 years - 70 yearsA Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
HIC ID2000029678RoleSub InvestigatorPrimary Completion Date12/15/2023Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Clinical Specialties
Medical Oncology
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale MedicineInflammatory Breast Cancer
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
Smilow Shares: Breast Cancer Awareness Month: Early-Stage Breast Cancer
October 9, 2025
Moderated by: Rachel Greenup, MD, MPH
Presentations by:
Elizabeth Berger, MD, MS, FACS
Mariya Rozenblit, MD
Siba Haykal, MD, PhD, FRCS, FACS
News
- September 28, 2025
YCC Publications 2025
- May 22, 2025
2025 ASCO Conquer Cancer Grants & Awards Announced
- April 08, 2025
Comprehensive Breast Cancer Care at Smilow Cancer Hospital at Greenwich and Stamford
- April 01, 2025
Smilow Shares with Primary Care: Breast Cancer Screening
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.